Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
3.360
+0.010 (0.30%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Neuphoria Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Cash & Equivalents | 19.87 | 14.21 | 12.61 | 12.1 | 23.13 |
Cash & Short-Term Investments | 19.87 | 14.21 | 12.61 | 12.1 | 23.13 |
Cash Growth | 39.79% | 12.71% | 4.17% | -47.66% | 8.23% |
Other Receivables | 0.81 | 0.01 | 0.13 | 0.43 | 4.67 |
Receivables | 0.81 | 0.01 | 0.13 | 0.43 | 4.67 |
Prepaid Expenses | 0.39 | 0.74 | 0.46 | 0.8 | 1.01 |
Restricted Cash | - | 0.08 | - | - | - |
Total Current Assets | 21.07 | 15.04 | 13.19 | 13.33 | 28.81 |
Property, Plant & Equipment | - | 0.11 | 0.22 | 0.33 | 0.46 |
Goodwill | 3.5 | 8.64 | 8.69 | 8.69 | 8.87 |
Other Intangible Assets | 4.14 | 4.8 | 5.47 | 6.13 | 6.78 |
Other Long-Term Assets | - | - | 0.08 | 0.08 | 0.08 |
Total Assets | 28.71 | 28.59 | 27.65 | 28.56 | 45 |
Liabilities
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Accounts Payable | 0.39 | 1.15 | 2.24 | 1.44 | 1.07 |
Accrued Expenses | 0.28 | 2.88 | 1.39 | 1.19 | 1.13 |
Short-Term Debt | 0.03 | 0.03 | 0.03 | - | - |
Current Portion of Leases | - | 0.12 | 0.12 | 0.11 | 0.11 |
Other Current Liabilities | 0.05 | 0.04 | 0.04 | - | - |
Total Current Liabilities | 0.76 | 4.22 | 3.83 | 2.74 | 2.31 |
Long-Term Leases | - | - | 0.12 | 0.24 | 0.37 |
Pension & Post-Retirement Benefits | - | - | - | - | 0.01 |
Long-Term Deferred Tax Liabilities | 0.36 | 0.5 | 0.96 | 1.1 | 1.24 |
Other Long-Term Liabilities | 3 | 4.87 | 5.25 | 2.47 | 1.86 |
Total Liabilities | 4.11 | 9.59 | 10.16 | 6.55 | 5.79 |
Shareholders' Equity
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Common Stock | 0 | 0 | 0 | - | 149.99 |
Additional Paid-In Capital | 218.46 | 200.19 | 198.48 | 187.55 | - |
Retained Earnings | -191.8 | -178.35 | -177.98 | -162.48 | -119.41 |
Comprehensive Income & Other | -2.06 | -2.85 | -3.01 | -3.06 | 8.63 |
Shareholders' Equity | 24.6 | 19 | 17.49 | 22.01 | 39.21 |
Total Liabilities & Equity | 28.71 | 28.59 | 27.65 | 28.56 | 45 |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Total Debt | 0.03 | 0.15 | 0.27 | 0.35 | 0.48 |
Net Cash (Debt) | 19.83 | 14.06 | 12.34 | 11.75 | 22.65 |
Net Cash Growth | 41.03% | 13.99% | 4.99% | -48.12% | 9.32% |
Net Cash Per Share | 4.51 | 8.66 | 14.82 | 0.01 | 0.02 |
Filing Date Shares Outstanding | 5.41 | 2.36 | 3,118 | 1,469 | 1,353 |
Total Common Shares Outstanding | 5.41 | 1.98 | 2,385 | 1,469 | 1,353 |
Working Capital | 20.31 | 10.82 | 9.36 | 10.59 | 26.49 |
Book Value Per Share | 4.55 | 9.60 | 0.01 | 0.01 | 0.03 |
Tangible Book Value | 16.96 | 5.56 | 3.33 | 7.19 | 23.57 |
Tangible Book Value Per Share | 3.13 | 2.81 | 0.00 | 0.00 | 0.02 |